Bioage Labs Inc/$BIOA
1D1W1MYTD1Y5YMAX
Capital at risk
About Bioage Labs Inc
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
- Ticker
- $BIOA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 61
- Headquarters
- EmeryVille, United States
- Website
- bioagelabs.com
Bioage Labs Inc Metrics
BasicAdvanced
$389M
-
-$2.37
-
-
Price and volume
Market cap
$389M
52-week high
$25.96
52-week low
$4.68
Average daily volume
755K
Financial strength
Current ratio
17.189
Quick ratio
16.619
Long term debt to equity
0.006
Total debt to equity
0.008
Interest coverage (TTM)
-378.19%
Profitability
EBITDA (TTM)
-106.02
Gross margin (TTM)
-747.78%
Net profit margin (TTM)
-912.25%
Operating margin (TTM)
-1,026.28%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
-18.47%
Return on equity (TTM)
-28.21%
Valuation
Price to revenue (TTM)
32.627
Price to book
1.04
Price to tangible book (TTM)
1.04
Price to free cash flow (TTM)
-3.835
Free cash flow yield (TTM)
-26.07%
Free cash flow per share (TTM)
-2.211
Growth
Revenue change (TTM)
168.06%
Earnings per share change (TTM)
-16.58%
Bulls say / Bears say
In January 2026, BioAge announced additional positive interim Phase 1 data for BGE-102, demonstrating potential best-in-class reductions in hsCRP and a favorable safety profile in participants with elevated cardiovascular risk (Reuters).
As of June 30, 2026, BioAge held $381.3 million in cash and marketable securities, providing an estimated runway through 2029 to fund ongoing clinical programs without near-term financing needs (Reuters).
In June 2026, BioAge dosed the first participant in its QUELL-CV Phase 2 proof-of-concept trial of BGE-102, marking its transition into mid-stage development with topline data expected in the second half of 2026 (Reuters).
BioAge’s net loss widened to $26.1 million in Q2 2026, with R&D expenses rising to $24.4 million as costs ramped up for its BGE-102 programs, underscoring its substantial burn rate (Reuters).
Despite advancing BGE-102 into a Phase 2 trial, BioAge will not report topline QUELL-CV data until H2 2026, and its diabetic macular edema study only commenced in mid-2026, deferring critical proof-of-concept milestones (Reuters).
Collaboration revenue of $2.4 million in Q2 2026 covered only a fraction of its $26.1 million net loss, highlighting reliance on equity financing to sustain operations (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
Upcoming events
No upcoming events
Bioage Labs Inc News
AllArticlesVideos
Funds containing Bioage Labs Inc
AllUSDGBPEUR
Fund name | Fund size | $BIOA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.